DRG Market Assessment Reports

Report March 20, 2014

Cognitive Impairment Associated with Schizophrenia | DecisionBase | US/EU | 2014

What Clinical Attributes Will Be Most Persuasive for Psychiatrists and Payers Regarding the First Novel Drugs in this Highly Underserved Arena? Decision Resources Group forecasts the number of…

north_east

Report March 20, 2014

Multiple Sclerosis (Chronic-Progressive) | Decision Base | US | 2014

Amid Substantial Unmet Need, What Magnitude of Efficacy and Safety Do Neurologists and Payers Expect of a First-To-Market Therapy for Primary-Progressive Multiple Sclerosis? Despite contributing…

north_east

Report March 20, 2014

Cognitive Impairment Associated with Schizophrenia | Decision Base | US | 2014

What Clinical Attributes Will Be Most Persuasive for Psychiatrists and Payers Regarding the First Novel Drugs in this Highly Underserved Arena? Decision Resources Group forecasts the number of…

north_east

Report March 17, 2014

Malignant Melanoma [Tafinlar and Mekinist (Wave 2)] | LaunchTrends | US | 2014

LaunchTrends: Tafinlar and Mekinist is a series of three post-launch syndicated reports designed to track physician perception and uptake of newly launched Tafinlar (GlaxoSmithKline’s dabrafenib…

north_east

Report March 14, 2014

Multiple Sclerosis | TreatmentTrends | US | Q1 2014

TreatmentTrends: Multiple Sclerosis (US) is an annual syndicated report that provides a comprehensive view of the current and anticipated management of multiple sclerosis (MS) based on primary…

north_east

Report March 14, 2014

Breast Cancer (The Expanding Role of Targeted Agents in Breast Cancer: Physician and Payer Receptivity to the Integration of Novel Premium-Priced Therapies in Highly Generic Market Segments) | Physician & Payer Forum | US | 2014

Treatment for breast cancer (CaB) in the United States has matured as oncologists have formalized protocols around specific patient populations, namely HER2+, HR+/HER2-, and HR-/HER2- (also known…

north_east

Report March 13, 2014

Multiple Sclerosis (Relapsing-Remitting) | DecisionBase | US/EU | 2014

How Will the Complex Interplay Between Benefit, Risk, and Cost Impact Prescriber Preferences, and Payer Acceptance of, Future Disease-Modifying Therapies? The market for disease-modifying…

north_east

Report March 13, 2014

Multiple Sclerosis (Relapsing-Remitting) | DecisionBase | US/EU | 2014

How Will the Complex Interplay Between Benefit, Risk, and Cost Impact Prescriber Preferences, and Payer Acceptance of, Future Disease-Modifying Therapies? The market for disease-modifying…

north_east

Report March 13, 2014

Opioid Addiction | DecisionBase | US/EU5 | 2014

How Will Physicians and Payers Value Advances in Drug Delivery? Opioid addiction is a debilitating, chronic relapsing disorder affecting nearly 5 million people in the seven major markets under…

north_east

Report March 13, 2014

Opioid Addiction | Decision Base | [Geography] | 2014

How Will Physicians and Payers Value Advances in Drug Delivery? Opioid addiction is a debilitating, chronic relapsing disorder affecting nearly 5 million people in the seven major markets under…

north_east

Report March 10, 2014

Sovaldi and Olysio (Hepatitis C Virus) (Wave 1) | LaunchTrends | US | 2014

Hepatitis C virus (HCV) chronic infections are a leading cause of advanced liver disease and hepatocellular carcinoma. The first-generation protease inhibitors were a major advancement in the…

north_east

Report March 10, 2014

LaunchTrends: Perjeta and Kadcyla (Breast Cancer) (US) (Wave 4) | 2014

LaunchTrends®: Perjeta and Kadcyla is a series of four post-launch syndicated reports designed to track physician perception and uptake of newly launched Perjeta (Roche/Genentech’s pertuzumab)…

north_east

Product logins

DRG Market Assessment reports

Cognitive Impairment Associated with Schizophrenia | DecisionBase | US/EU | 2014

Multiple Sclerosis (Chronic-Progressive) | Decision Base | US | 2014

Cognitive Impairment Associated with Schizophrenia | Decision Base | US | 2014

Malignant Melanoma [Tafinlar and Mekinist (Wave 2)] | LaunchTrends | US | 2014

Multiple Sclerosis | TreatmentTrends | US | Q1 2014

Breast Cancer (The Expanding Role of Targeted Agents in Breast Cancer: Physician and Payer Receptivity to the Integration of Novel Premium-Priced Therapies in Highly Generic Market Segments) | Physician & Payer Forum | US | 2014

Multiple Sclerosis (Relapsing-Remitting) | DecisionBase | US/EU | 2014

Multiple Sclerosis (Relapsing-Remitting) | DecisionBase | US/EU | 2014

Opioid Addiction | DecisionBase | US/EU5 | 2014

Opioid Addiction | Decision Base | [Geography] | 2014

Sovaldi and Olysio (Hepatitis C Virus) (Wave 1) | LaunchTrends | US | 2014

LaunchTrends: Perjeta and Kadcyla (Breast Cancer) (US) (Wave 4) | 2014

Follow us

Contact us